Downregulating CEBPD can lead to reduced neurofunctional deficits, smaller infarct sizes, improved cell survival, and decreased apoptosis and oxidative stress both in vivo and in vitro, suggesting that CEBPD could be a new target for stroke treatment [28]. This evidence concerns the gene CEBPD and Stroke.